Mibampator

Mibampator

Systematic (IUPAC) name
N-[(2R)-2-[4-[4-[2-(methanesulfonamido)ethyl]phenyl]phenyl]propyl]propane-2-sulfonamide
Identifiers
CAS Number	375345-95-2
PubChem	CID: 9889366
ChemSpider	8065037
UNII	A9V5BW73UU
KEGG	D09931
ChEMBL	CHEMBL1277001
Synonyms	LY-451395
Chemical data
Formula	C21H30N2O4S2
Molecular mass	438.601 g/mol
SMILES C[C@@H](CNS(=O)(=O)C(C)C)C1=CC=C(C=C1)C2=CC=C(C=C2)CCNS(=O)(=O)C
InChI InChI=1S/C21H30N2O4S2/c1-16(2)29(26,27)23-15-17(3)19-9-11-21(12-10-19)20-7-5-18(6-8-20)13-14-22-28(4,24)25/h5-12,16-17,22-23H,13-15H2,1-4H3/t17-/m0/s1 Key:ULRDYYKSPCRXAJ-KRWDZBQOSA-N

Mibampator (developmental code name LY-451395) is a positive allosteric modulator of the AMPA receptor (AMPAR), an ionotropic glutamate receptor, which was under development by Eli Lilly for the treatment of agitation/aggression in Alzheimer's disease but was never marketed. It is a "high-impact" AMPAR potentiator, unlike "low-impact" AMPAR potentiators like CX-516 and its congener farampator (CX-691), and is able to elicit more robust increases in AMPAR signaling. In animals, high-impact AMPAR potentiators enhance cognition and memory at low doses, but produce motor coordination disruptions, convulsions, and neurotoxicity at higher doses. Mibampator failed to produce cognitive improvement in patients with Alzheimer's disease, though it did show improvements in neuropsychiatric measures. A caveat of the study was that the maximally tolerated dosage of the drug could not be used due to toxicity, and dosages in the same range in rodents notably failed to improve memory-related behavior. Mibampator reached phase II clinical trials prior to the discontinuation of its development.

See also

• PF-04958242

External links

• Mibampator - AdisInsight